Cargando…
IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory, follicular skin disease whose pathology is complex and not fully understood. The objective of this study was to elucidate the role of IL‐17A in moderate‐to‐severe HS. Transcriptomic and histological analyses were conducted on ex vi...
Autores principales: | Kimball, Alexa B., Loesche, Christian, Prens, Errol P., Bechara, Falk G., Weisman, Jamie, Rozenberg, Izabela, Jarvis, Philip, Peters, Thomas, Roth, Lukas, Wieczorek, Grazyna, Kolbinger, Frank, Jemec, Gregor B. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804780/ https://www.ncbi.nlm.nih.gov/pubmed/35638561 http://dx.doi.org/10.1111/exd.14619 |
Ejemplares similares
-
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa
por: Gulliver, Wayne, et al.
Publicado: (2016) -
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial
por: Kimball, Alexa B., et al.
Publicado: (2023) -
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial
por: Bechara, Falk G., et al.
Publicado: (2021) -
Hidradenitis suppurativa and intimacy
por: Jemec, G.
Publicado: (2018) -
Multimodal management of hidradenitis suppurativa
por: Jemec, Gregor B.E.
Publicado: (2020)